First Time Loading...

Reneo Pharmaceuticals Inc
NASDAQ:RPHM

Watchlist Manager
Reneo Pharmaceuticals Inc Logo
Reneo Pharmaceuticals Inc
NASDAQ:RPHM
Watchlist
Price: 1.65 USD -1.79% Market Closed
Updated: Apr 27, 2024

Intrinsic Value

RPHM's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Reneo Pharmaceuticals, Inc. is a clinical-stage company, which engages in the research and development of therapies for rare genetic mitochondrial diseases. [ Read More ]

The intrinsic value of one RPHM stock under the Base Case scenario is 9.77 USD. Compared to the current market price of 1.65 USD, Reneo Pharmaceuticals Inc is Undervalued by 83%.

Key Points:
RPHM Intrinsic Value
Base Case
9.77 USD
Undervaluation 83%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Reneo Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling RPHM stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Reneo Pharmaceuticals Inc

Provide an overview of the primary business activities
of Reneo Pharmaceuticals Inc.

What unique competitive advantages
does Reneo Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Reneo Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Reneo Pharmaceuticals Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Reneo Pharmaceuticals Inc.

Provide P/S
for Reneo Pharmaceuticals Inc.

Provide P/E
for Reneo Pharmaceuticals Inc.

Provide P/OCF
for Reneo Pharmaceuticals Inc.

Provide P/FCFE
for Reneo Pharmaceuticals Inc.

Provide P/B
for Reneo Pharmaceuticals Inc.

Provide EV/S
for Reneo Pharmaceuticals Inc.

Provide EV/GP
for Reneo Pharmaceuticals Inc.

Provide EV/EBITDA
for Reneo Pharmaceuticals Inc.

Provide EV/EBIT
for Reneo Pharmaceuticals Inc.

Provide EV/OCF
for Reneo Pharmaceuticals Inc.

Provide EV/FCFF
for Reneo Pharmaceuticals Inc.

Provide EV/IC
for Reneo Pharmaceuticals Inc.

Show me price targets
for Reneo Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Reneo Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Reneo Pharmaceuticals Inc?

What are the Net Income projections
for Reneo Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Reneo Pharmaceuticals Inc?

What are the EPS projections
for Reneo Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Reneo Pharmaceuticals Inc?

What are the EBIT projections
for Reneo Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Reneo Pharmaceuticals Inc?

Compare the revenue forecasts
for Reneo Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Reneo Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Reneo Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Reneo Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Reneo Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Reneo Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Reneo Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Reneo Pharmaceuticals Inc.

Provide ROE
for Reneo Pharmaceuticals Inc.

Provide ROA
for Reneo Pharmaceuticals Inc.

Provide ROIC
for Reneo Pharmaceuticals Inc.

Provide ROCE
for Reneo Pharmaceuticals Inc.

Provide Gross Margin
for Reneo Pharmaceuticals Inc.

Provide Operating Margin
for Reneo Pharmaceuticals Inc.

Provide Net Margin
for Reneo Pharmaceuticals Inc.

Provide FCF Margin
for Reneo Pharmaceuticals Inc.

Show all solvency ratios
for Reneo Pharmaceuticals Inc.

Provide D/E Ratio
for Reneo Pharmaceuticals Inc.

Provide D/A Ratio
for Reneo Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Reneo Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Reneo Pharmaceuticals Inc.

Provide Quick Ratio
for Reneo Pharmaceuticals Inc.

Provide Current Ratio
for Reneo Pharmaceuticals Inc.

Provide Cash Ratio
for Reneo Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Reneo Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Reneo Pharmaceuticals Inc?

What is the current Free Cash Flow
of Reneo Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Reneo Pharmaceuticals Inc.

Financials

Balance Sheet Decomposition
Reneo Pharmaceuticals Inc

Current Assets 106.6m
Cash & Short-Term Investments 103m
Other Current Assets 3.7m
Non-Current Assets 814k
PP&E 733k
Other Non-Current Assets 81k
Current Liabilities 18.2m
Accounts Payable 8.7m
Accrued Liabilities 9.5m
Non-Current Liabilities 649k
Other Non-Current Liabilities 649k
Efficiency

Earnings Waterfall
Reneo Pharmaceuticals Inc

Revenue
0 USD
Operating Expenses
-83.1m USD
Operating Income
-83.1m USD
Other Expenses
5.7m USD
Net Income
-77.4m USD

Free Cash Flow Analysis
Reneo Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

RPHM Profitability Score
Profitability Due Diligence

Reneo Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score

Reneo Pharmaceuticals Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

RPHM Solvency Score
Solvency Due Diligence

Reneo Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Reneo Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RPHM Price Targets Summary
Reneo Pharmaceuticals Inc

Wall Street analysts forecast RPHM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RPHM is 1.71 USD with a low forecast of 1.01 USD and a high forecast of 3.15 USD.

Lowest
Price Target
1.01 USD
39% Downside
Average
Price Target
1.71 USD
4% Upside
Highest
Price Target
3.15 USD
91% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

RPHM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

RPHM Price
Reneo Pharmaceuticals Inc

1M 1M
+0%
6M 6M
-79%
1Y 1Y
-84%
3Y 3Y
-88%
5Y 5Y
-88%
10Y 10Y
-88%
Annual Price Range
1.65
52w Low
1.34
52w High
10.22
Price Metrics
Average Annual Return -54.28%
Standard Deviation of Annual Returns 25.55%
Max Drawdown -91%
Shares Statistics
Market Capitalization 55.1m USD
Shares Outstanding 33 420 808
Percentage of Shares Shorted 14.55%

RPHM Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Reneo Pharmaceuticals Inc Logo
Reneo Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

55.1m USD

Dividend Yield

0%

Description

Reneo Pharmaceuticals, Inc. is a clinical-stage company, which engages in the research and development of therapies for rare genetic mitochondrial diseases. The company is headquartered in Irvine, California and currently employs 20 full-time employees. The company went IPO on 2021-04-09. The firm is focused on the developing therapies for patients with rare genetic mitochondrial diseases. The firm is engaged in developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the source of energy for cellular processes. REN001 is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist that has been shown to transcription of genes involved in mitochondrial function and fatty acid oxidation (FAO). The firm is developing REN001 in the three rare genetic diseases that present with myopathy and have unmet medical need: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disease type V (McArdle disease). The firm has completed Phase I b clinical trial in patients with PMM to REN001. The company is conducting open-label Phase I b clinical trials of REN001 with LC-FAOD and with McArdle disease.

Contact

CALIFORNIA
Irvine
18575 Jamboree Road, Suite 275-S
+18582830280.0
https://reneopharma.com/

IPO

2021-04-09

Employees

20

Officers

Founder & Executive Chairman
Mr. Michael G. Grey
President, CEO & Director
Mr. Gregory J. Flesher
Chief Operating Officer
Mr. Michael P. Cruse
Chief Development Officer
Ms. Ashley F. Hall J.D.
Senior VP of Finance, Principal Financial & Accounting Officer
Ms. Jennifer P. Lam
Chief Medical Officer
Dr. Alejandro Dorenbaum M.D.
Show More
Senior Vice President of Global Development
Ms. Lynn Purkins Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one RPHM stock?

The intrinsic value of one RPHM stock under the Base Case scenario is 9.77 USD.

Is RPHM stock undervalued or overvalued?

Compared to the current market price of 1.65 USD, Reneo Pharmaceuticals Inc is Undervalued by 83%.